Skip to main content

Diagnosis codes for coagulation disorders.

Claim forms typically require an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or Tenth Revision (ICD-10-CM) diagnosis code.

It may be appropriate to use one of the diagnosis codes below for patients treated with NovoSeven® RT.

List of ICD-9 and ICD-10 diagnosis codes

Hemophilia A (FVIII deficiency)

ICD-9-CM1       ICD-10-CM2

286.0                 D66

Hemophilia B (FIX deficiency)

ICD-9-CM1       ICD-10-CM2
286.1                 D67

Other hereditary factor deficiencies (including FVII deficiency)

ICD-9-CM1       ICD-10-CM2

286.3                D68.2

Acquired hemophilia

ICD-9-CM1       ICD-10-CM2

286.52            D68.311

Other hemorrhagic disorder due to intrinsic circulation anticoagulants, antibodies, or inhibitors

ICD-9-CM1       ICD-10-CM2

286.59            D68.318

Glanzmann's thrombasthenia
(listed under "Qualitative Platelet Defects")

ICD-9-CM1       ICD-10-CM2

287.1                 D69.1

NovoSeven® RT Infusion Code

J code3

J7189

J code                  J7189

Icon of five people standing

Have a question? We’re

here to help.


Box of NovoSeven® RT (Coagulation Factor VIIa [Recombinant])

How to order

NovoSeven® RT.


Acquired hemophilia bruising photos

Interested in acquired

hemophilia?

Selected Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for Prescribing Information

References:

  1. Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). ftp://ftp.cdc.gov/pub/Health_Statistics/NICHS/Publications/ICD9-CM2011/. Updated June 18, 2013. Accessed December 10, 2015.
  2. Centers for Disease Control and Prevention. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). http://www.cdc.gov/nchs/icd/icd10cm.htm#icd2016. Updated October 29, 2015. Accessed January 8, 2016.
  3. Centers for Medicare & Medicaid Services, 2015 HCPCS alpha-numeric index.  
    https://www.cms.gov/medicare/coding/medhcpcsgeninfo/index.html. Accessed January 8, 2016.